and bio-specimens of patients with severe DILI from 13 medical centers across the mainland.
The first report of 300 enrolled cases from DILIN disclosed that antimicrobial drugs are the leading cause of DILI in the USA (45.5%), followed by central nervous system agents (15%). 1 Fourteen percent of patients had developed chronic liver injury, and 8% had died.
Recently, the international Drug-Induced Liver Injury Consortium (iDILIC), set up by the European non-profit international Severe Adverse Events Consortium (iSAEC), has collected bio-specimens and data for DILI globally (mainly from Europe) and published a first multinational genome-wide association study (GWAS) of human leukocyte antigen (HLA) and amoxicillineclavulanate-induced hepatotoxicity. 2 They found some class I and II HLA genotypes may affect the susceptibility and severity of this most prevalent form of DILI in Europe and USA. The other remarkable finding is the GWAS of flucloxacillin-induced hepatotoxicity and HLA from the UK. They revealed patients with HLA-B*5701 have significantly higher risk of having flucloxacillin-induced liver injury (odds ratio Z 80.6). 3 This highlights the value of genetic studies in understanding the mechanism of DILI and posits a successful model for further clinical application.
In Taiwan, only a few single-center studies about DILI have been reported. 4e10 A national database of DILI was not established until 2011 when the Drug-Induced Liver Injury Network in Taiwan (DILINT) was launched, sponsored by the Taiwan Food and Drug Administration (Fig. 1 ). This is a multi-center collaborative program to collect the clinical data of DILI prospectively and retrospectively from six medical centers across the island. The preliminary data showed that antituberculosis drugs are the leading discriminated agents (27.8%), followed by herbs (20.5%), and antibiotics (10.0%) (unpublished data). The finding that antituberculosis drugs and herbs play major roles in DILI in Taiwan is consistent with findings in mainland China, Hong Kong, Singapore, Korea and many other countries. This spotlights the urgent need for a pharmacovigilance program covering both conventional, Western drugs and herbs.
Global endeavors in the early detection and prevention of DILI have been developed over the past decade, based on the gradually growing database. In addition to the abovementioned association study of HLA, assaying functional genetic polymorphisms of the target drug-metabolizing enzymes is another way to detect the susceptibility genetic factors of DILI. Since antituberculosis drugs are the leading culprits for DILI in Taiwan and many Asian countries, we have recently performed a series of pharmacogenetic association studies in this field. We found that patients with N-acetyltransferase 2 (NAT2) slow acetylator status, cytochrome P450 2E1(CYP2E1) wild c1/c1 genotype, glutathione S-transferase M1(GSTM1) null genotype, and manganese superoxide dismutase (MnSOD, SOD2) mutant C allele may be at higher risk of antituberculosis DILI. Patients with all of these risk genotypes may have more than a 10-fold higher risk of antituberculosis DILI than those without these genotypes. Although these associations need to be verified in other ethnic populations with a larger sample size, this kind of pharmacogenetic or pharmacogenomic approach reveals the potential of early detection and prevention of DILI caused by some drugs.
A good pharmacovigilance system, which includes detection of severe DILI, is the hallmark of high-quality healthcare. By combining the experience and insight of the various DILI networks and organizations, we could achieve an extraordinary opportunity to combat DILI. International collaboration to collect and share database and biospecimen repository is just on the way. Further effort is needed to initiate some large-scale international studies for detecting biomarkers of severe DILI. Through international efforts and progress in pharmacogenetics and pharmacogenomics, we then can mitigate DILI and guarantee drug safety further. Drug Relief Foundation is a nonprofit organization authorized by the Taiwan Food and Drug Administration to manage the compensation system of severe adverse drug reaction. DILI Z drug-induced liver injury.
